In a move to expand its oncology business, GSK is nearing a $1 billion deal to buy a US biotech developing a treatment for rare gastrointestinal tumors.

GlaxoSmithKline (GSK) agreed to acquire a clinical-stage drug from Chimagen Biosciences, a privately held Chinese biotechnology company. CMG1A46 is a dual CD19 and CD20...

British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US...

GSK and innovation company Flagship Pioneering have entered a collaboration to develop a portfolio of new medicines and vaccines, starting in respiratory and immunology...

Touchlight, a UK-based custom development and manufacturing organization (CDMO) specializing in enzymatic DNA production, signed a license agreement with British...

GSK has agreed to acquire biotech Aiolos Bio for a $1 billion upfront payment and up to $400 million for the achievement of certain milestones. Founded just last year...

GSK has struck a deal with Chongqing Zhifei Biological Products to promote the British group's shingles vaccine, Shingrix, in China for an initial three-year period...

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...